Skip to main content

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
Cancel
×
×
Home
  • Home
Article
  • Cited by 7
  • Cited by
    Crossref Citations
    Crossref logo
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.
    Fernando, W.M.A.D. Binosha Rainey-Smith, Stephanie R. Gardener, Samantha L. Villemagne, Victor L. Burnham, Samantha C. Macaulay, S. Lance Brown, Belinda M. Gupta, Veer Bala Sohrabi, Hamid R. Weinborn, Michael Taddei, Kevin Laws, Simon M. Goozee, Kathryn Ames, David Fowler, Christopher Maruff, Paul Masters, Colin L. Salvado, Olivier Rowe, Christopher C. and Martins, Ralph N. 2018. Associations of Dietary Protein and Fiber Intake with Brain and Blood Amyloid-β. Journal of Alzheimer's Disease, Vol. 61, Issue. 4, p. 1589.
    Boccardi, Virginia Tinarelli, Clara and Mecocci, Patrizia 2017. Neuroprotective Effects of Phytochemicals in Neurological Disorders. p. 561.
    Cahill, Michael A. and Medlock, Amy E. 2017. Thoughts on interactions between PGRMC1 and diverse attested and potential hydrophobic ligands. The Journal of Steroid Biochemistry and Molecular Biology, Vol. 171, Issue. , p. 11.
    Wade, Alexandra Davis, Courtney Dyer, Kathryn Hodgson, Jonathan Woodman, Richard Keage, Hannah and Murphy, Karen 2017. A Mediterranean Diet to Improve Cardiovascular and Cognitive Health: Protocol for a Randomised Controlled Intervention Study. Nutrients, Vol. 9, Issue. 2, p. 145.
    Salameh, Therese S Rhea, Elizabeth M Banks, William A and Hanson, Angela J 2016. Insulin resistance, dyslipidemia, and apolipoprotein E interactions as mechanisms in cognitive impairment and Alzheimer's disease. Experimental Biology and Medicine, Vol. 241, Issue. 15, p. 1676.
    Bamburg, James R. and Bernstein, Barbara W. 2016. Actin dynamics and cofilin-actin rods in alzheimer disease. Cytoskeleton, Vol. 73, Issue. 9, p. 477.
    Li, Wen Jiang, Mingyue Zhao, Shijing Liu, Huan Zhang, Xumei Wilson, John and Huang, Guowei 2015. Folic Acid Inhibits Amyloid β-Peptide Production through Modulating DNA Methyltransferase Activity in N2a-APP Cells. International Journal of Molecular Sciences, Vol. 16, Issue. 10, p. 25002.
    ×
  • Access

Diet, nutrients and metabolism: cogs in the wheel driving Alzheimer's disease pathology?

  • Rhona Creegan (a1) (a2), Wendy Hunt (a1) (a2), Alexandra McManus (a1) (a2) and Stephanie R. Rainey-Smith (a3) (a4)
Abstract

Alzheimer's disease (AD), the most common form of dementia, is a chronic, progressive neurodegenerative disease that manifests clinically as a slow global decline in cognitive function, including deterioration of memory, reasoning, abstraction, language and emotional stability, culminating in a patient with end-stage disease, totally dependent on custodial care. With a global ageing population, it is predicted that there will be a marked increase in the number of people diagnosed with AD in the coming decades, making this a significant challenge to socio-economic policy and aged care. Global estimates put a direct cost for treating and caring for people with dementia at $US604 billion, an estimate that is expected to increase markedly. According to recent global statistics, there are 35·6 million dementia sufferers, the number of which is predicted to double every 20 years, unless strategies are implemented to reduce this burden. Currently, there is no cure for AD; while current therapies may temporarily ameliorate symptoms, death usually occurs approximately 8 years after diagnosis. A greater understanding of AD pathophysiology is paramount, and attention is now being directed to the discovery of biomarkers that may not only facilitate pre-symptomatic diagnosis, but also provide an insight into aberrant biochemical pathways that may reveal potential therapeutic targets, including nutritional ones. AD pathogenesis develops over many years before clinical symptoms appear, providing the opportunity to develop therapy that could slow or stop disease progression well before any clinical manifestation develops.

  • View HTML
      • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Diet, nutrients and metabolism: cogs in the wheel driving Alzheimer's disease pathology?
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Diet, nutrients and metabolism: cogs in the wheel driving Alzheimer's disease pathology?
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Diet, nutrients and metabolism: cogs in the wheel driving Alzheimer's disease pathology?
      Available formats
      ×
Copyright
COPYRIGHT: © The Authors 2015 
Corresponding author
* Corresponding author: Dr R. Creegan, fax +61 8 9341 1615, email rhobru@iinet.net.au
References
Hide All
1 Blennow, K, de Leon, MJ & Zetterberg, H (2006) Alzheimer's disease. Lancet 368, 387–403.
2 Roses, A, Alberts, M & Strittmatter, W (1992) Alzheimer's disease – reassessing the data. Curr Biol 2, 7–9.
3 Brookmeyer, R, Johnson, E, Ziegler-Graham, K, et al. (2007) Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3, 186–191.
4 Ferri, CP, Prince, M, Brayne, C, et al. (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366, 2112–2117.
5 Dementia across Australia 2011–2050 (2011) Deloitte access economics for Alzheimer's Australia.
6 Access, delaying onset of Alzheimer's disease: predictions and issues (internet) 2004–2009 report no. 30.
7 Kidd, PM (2008) Alzheimer's disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention. Altern Med Rev 13, 85–115.
8 Verdile, G, Fuller, S, Atwood, CS, et al. (2004) The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught? Pharmacol Res 50, 397–409.
9 Borroni, B, Akkawi, N, Martini, G, et al. (2002) Microvascular damage and platelet abnormalities in early Alzheimer's disease. J Neurol Sci 203–204, 189–193.
10 Krishnaswamy, S, Verdile, G, Groth, D, et al. (2009) The structure and function of Alzheimer's gamma secretase enzyme complex. Crit Rev Clin Lab Sci 46, 282–301.
11 De Strooper, B (2010) Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol Rev 90, 465–494.
12 Castellani, RJ, Lee, HG, Siedlak, SL, et al. (2009) Reexamining Alzheimer's disease: evidence for a protective role for amyloid-beta protein precursor and amyloid-beta. J Alzheimers Dis 18, 447–452.
13 Ballatore, C, Lee, VM & Trojanowski, JQ (2007) Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 8, 663–672.
14 Small, SA & Duff, K (2008) Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron 60, 534–542.
15 Liang, Z, Liu, F, Iqbal, K, et al. (2009) Dysregulation of tau phosphorylation in mouse brain during excitotoxic damage. J Alzheimers Dis 17, 531–539.
16 Iqbal, K, Liu, F, Gong, CX, et al. (2009) Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 118, 53–69.
17 Corder, EH, Saunders, AM, Strittmatter, WJ, et al. (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921–923.
18 Di Paolo, G & Kim, TW (2011) Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat Rev Neurosci 12, 284–296.
19 Han, X (2010) Multi-dimensional mass spectrometry-based shotgun lipidomics and the altered lipids at the mild cognitive impairment stage of Alzheimer's disease. Biochim Biophys Acta 1801, 774–783.
20 Han, X & Gross, RW (2005) Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom Rev 24, 367–412.
21 Frisardi, V, Panza, F, Seripa, D, et al. (2011) Glycerophospholipids and glycerophospholipid-derived lipid mediators: a complex meshwork in Alzheimer's disease pathology. Prog Lipid Res 50, 313–330.
22 Farooqui, AA, Farooqui, T, Panza, F, et al. (2012) Metabolic syndrome as a risk factor for neurological disorders. Cell Mol Life Sci 69, 741–762.
23 Frisardi, V & Imbimbo, BP (2012) Metabolic-cognitive syndrome: metabolic approach for the management of Alzheimer's disease risk. J Alzheimers Dis 30, Suppl. 2, S1–S4.
24 Craft, S (2009) The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch Neurol 66, 300–305.
25 Merlo, S, Spampinato, S, Canonico, PL, et al. (2010) Alzheimer's disease: brain expression of a metabolic disorder? Trends Endocrinol Metab 21, 537–544.
26 Luchsinger, JA (2012) Type 2 diabetes and cognitive impairment: linking mechanisms. J Alzheimers Dis 30, Suppl. 2, S185–S198.
27 Moreira, PI (2012) Alzheimer's disease and diabetes: an integrative view of the role of mitochondria, oxidative stress, and insulin. J Alzheimers Dis 30, Suppl. 2, S199–S215.
28 Kim, JK, Fillmore, JJ, Chen, Y, et al. (2001) Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A 98, 7522–7527.
29 Shulman, GI (2000) Cellular mechanisms of insulin resistance. J Clin Invest 106, 171–176.
30 Yu, C, Chen, Y, Cline, GW, et al. (2002) Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 277, 50230–50236.
31 Borst, SE (2004) The role of TNF-alpha in insulin resistance. Endocrine 23, 177–182.
32 Ruan, H & Lodish, HF (2003) Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev 14, 447–455.
33 Arbo, I, Halle, C, Malik, D, et al. (2011) Insulin induces fatty acid desaturase expression in human monocytes. Scand J Clin Lab Invest 71, 330–339.
34 Lopez-Ramirez, MA, Wu, D, Pryce, G, et al. (2014) MicroRNA-155 negatively affects blood–brain barrier function during neuroinflammation. FASEB J 28, 2551–2565.
35 Craft, S (2005) Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging 26, Suppl. 1, 65–69.
36 Chiu, SL, Chen, CM & Cline, HT (2008) Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo . Neuron 58, 708–719.
37 Shoelson, SE, Lee, J & Goldfine, AB (2006) Inflammation and insulin resistance. J Clin Invest 116, 1793–1801.
38 Chavez, JA & Summers, SA (2012) A ceramide-centric view of insulin resistance. Cell Metab 15, 585–594.
39 Summers, SA (2006) Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res 45, 42–72.
40 van Asselt, DZ, de Groot, LC, van Staveren, WA, et al. (1998) Role of cobalamin intake and atrophic gastritis in mild cobalamin deficiency in older Dutch subjects. Am J Clin Nutr 68, 328–334.
41 Krasinski, SD, Russell, RM, Samloff, IM, et al. (1986) Fundic atrophic gastritis in an elderly population. Effect on hemoglobin and several serum nutritional indicators. J Am Geriatr Soc 34, 800–806.
42 Obeid, R & Herrmann, W (2006) Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett 580, 2994–3005.
43 Tucker, KL, Qiao, N, Scott, T, et al. (2005) High homocysteine and low B vitamins predict cognitive decline in aging men: the Veterans Affairs Normative Aging Study. Am J Clin Nutr 82, 627–635.
44 Cropper, SS, Smith, JL & Groff, JL (2005) Advanced Nutrition and Human Metabolism, 4th ed. Belmont, CA: Thomson Wadsworth.
45 Polidori, MC, Pientka, L & Mecocci, P (2012) A review of the major vascular risk factors related to Alzheimer's disease. J Alzheimers Dis 32, 521–530.
46 Patterson, C, Feightner, J, Garcia, A, et al. (2007) General risk factors for dementia: a systematic evidence review. Alzheimers Dement 3, 341–347.
47 Luchsinger, JA & Mayeux, R (2004) Dietary factors and Alzheimer's disease. Lancet Neurol 3, 579–587.
48 Dosunmu, R, Wu, J, Basha, MR, et al. (2007) Environmental and dietary risk factors in Alzheimer's disease. Expert Rev Neurother 7, 887–900.
49 Schiepers, OJ, de Groot, RH, Jolles, J, et al. (2010) Fish consumption, not fatty acid status, is related to quality of life in a healthy population. Prostaglandins Leukot Essent Fatty Acids 83, 31–35.
50 Brayne, C, Gao, L, Matthews, F, et al. (2005) Challenges in the epidemiological investigation of the relationships between physical activity, obesity, diabetes, dementia and depression. Neurobiol Aging 26, Suppl. 1, 6–10.
51 Convit, A (2005) Links between cognitive impairment in insulin resistance: an explanatory model. Neurobiol Aging 26, Suppl. 1, 31–35.
52 Greenwood, CE & Winocur, G (2005) High-fat diets, insulin resistance and declining cognitive function. Neurobiol Aging 26, Suppl. 1, 42–45.
53 Brand-Miller, J, Hayne, S, Petocz, P, et al. (2003) Low-glycemic index diets in the management of diabetes: a meta-analysis of randomized controlled trials. Diabetes Care 26, 2261–2267.
54 Brand-Miller, JC (2003) Glycemic load and chronic disease. Nutr Rev 61, S49–S55.
55 Molteni, R, Barnard, RJ, Ying, Z, et al. (2002) A high-fat, refined sugar diet reduces hippocampal brain-derived neurotrophic factor, neuronal plasticity, and learning. Neuroscience 112, 803–814.
56 Stangl, D & Thuret, S (2009) Impact of diet on adult hippocampal neurogenesis. Genes Nutr 4, 271–282.
57 Kanoski, SE & Davidson, TL (2011) Western diet consumption and cognitive impairment: links to hippocampal dysfunction and obesity. Physiol Behav 103, 59–68.
58 Poo, MM (2001) Neurotrophins as synaptic modulators. Nat Rev Neurosci 2, 24–32.
59 Castren, E, Berninger, B, Leingartner, A, et al. (1998) Regulation of brain-derived neurotrophic factor mRNA levels in hippocampus by neuronal activity. Prog Brain Res 117, 57–64.
60 Scarmeas, N, Stern, Y, Tang, MX, et al. (2006) Mediterranean diet and risk for Alzheimer's disease. Ann Neurol 59, 912–921.
61 Gu, Y, Nieves, JW, Stern, Y, et al. (2010) Food combination and Alzheimer disease risk: a protective diet. Arch Neurol 67, 699–706.
62 Solfrizzi, V, Panza, F & Capurso, A (2003) The role of diet in cognitive decline. J Neural Transm 110, 95–110.
63 Morris, MC, Evans, DA, Bienias, JL, et al. (2002) Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA 287, 3230–3237.
64 Son, TG, Camandola, S & Mattson, MP (2008) Hormetic dietary phytochemicals. Neuromolecular Med 10, 236–246.
65 Gomez-Pinilla, F (2008) Brain foods: the effects of nutrients on brain function. Nat Rev Neurosci 9, 568–578.
66 Gomez-Pinilla, F (2008) The influences of diet and exercise on mental health through hormesis. Ageing Res Rev 7, 49–62.
67 Mattson, MP (2008) Hormesis and disease resistance: activation of cellular stress response pathways. Hum Exp Toxicol 27, 155–162.
68 Mattson, MP (2008) Dietary factors, hormesis and health. Ageing Res Rev 7, 43–48.
69 Sofi, F, Cesari, F, Abbate, R, et al. (2008) Adherence to Mediterranean diet and health status: meta-analysis. BMJ 337, a1344.
70 Panagiotakos, DB, Dimakopoulou, K, Katsouyanni, K, et al. (2009) Mediterranean diet and inflammatory response in myocardial infarction survivors. Int J Epidemiol 38, 856–866.
71 Dietschy, JM (1998) Dietary fatty acids and the regulation of plasma low density lipoprotein cholesterol concentrations. J Nutr 128, Suppl. 2, 444S–448S.
72 Woollett, LA, Spady, DK & Dietschy, JM (1992) Regulatory effects of the saturated fatty acids 6:0 through 18:0 on hepatic low density lipoprotein receptor activity in the hamster. J Clin Invest 89, 1133–1141.
73 Woollett, LA, Spady, DK & Dietschy, JM (1992) Saturated and unsaturated fatty acids independently regulate low density lipoprotein receptor activity and production rate. J Lipid Res 33, 77–88.
74 Caggiula, AW & Mustad, VA (1997) Effects of dietary fat and fatty acids on coronary artery disease risk and total and lipoprotein cholesterol concentrations: epidemiologic studies. Am J Clin Nutr 65, Suppl. 5, 1597S–1610S.
75 Kris-Etherton, PM & Yu, S (1997) Individual fatty acid effects on plasma lipids and lipoproteins: human studies. Am J Clin Nutr 65, Suppl. 5, 1628S–1644S.
76 Kris-Etherton, PM, Yu, S, Etherton, TD, et al. (1997) Fatty acids and progression of coronary artery disease. Am J Clin Nutr 65, 1088–1090.
77 Gill, JM & Sattar, N (2009) Ceramides: a new player in the inflammation-insulin resistance paradigm? Diabetologia 52, 2475–2477.
78 Han, X (2005) Lipid alterations in the earliest clinically recognizable stage of Alzheimer's disease: implication of the role of lipids in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2, 65–77.
79 Han, X, Holtzman, DM, McKeel, DW Jr, et al. (2002) Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J Neurochem 82, 809–818.
80 Matsuzaki, K (2010) Ganglioside cluster-mediated aggregation and cytotoxicity of amyloid beta-peptide: molecular mechanism and inhibition. Yakugaku Zasshi 130, 511–515 (in Japanese).
81 He, X, Huang, Y, Li, B, et al. (2010) Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol Aging 31, 398–408.
82 Grimm, MO, Haupenthal, VJ, Rothhaar, TL, et al. (2013) Effect of different phospholipids on alpha-secretase activity in the non-amyloidogenic pathway of Alzheimer's disease. Int J Mol Sci 14, 5879–5898.
83 Ascherio, A, Katan, MB, Zock, PL, et al. (1999) Trans fatty acids and coronary heart disease. N Engl J Med 340, 1994–1998.
84 Morris, MC, Evans, DA, Bienias, JL, et al. (2003) Dietary fats and the risk of incident Alzheimer disease. Arch Neurol 60, 194–200.
85 Bowman, GL, Silbert, LC, Howieson, D, et al. (2012) Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging. Neurology 78, 241–249.
86 Khan, SA & Vanden Heuvel, JP (2003) Role of nuclear receptors in the regulation of gene expression by dietary fatty acids (review). J Nutr Biochem 14, 554–567.
87 Vanden Heuvel, JP (2009) Cardiovascular disease-related genes and regulation by diet. Curr Atheroscler Rep 11, 448–455.
88 Vanden Heuvel, JP (2004) Diet, fatty acids, and regulation of genes important for heart disease. Curr Atheroscler Rep 6, 432–440.
89 Horrocks, LA & Farooqui, AA (2004) Docosahexaenoic acid in the diet: its importance in maintenance and restoration of neural membrane function. Prostaglandins Leukot Essent Fatty Acids 70, 361–372.
90 Sastry, PS (1985) Lipids of nervous tissue: composition and metabolism. Prog Lipid Res 24, 69–176.
91 Bordoni, A, Hrelia, S, Lorenzini, A, et al. (1998) Dual influence of aging and vitamin B6 deficiency on delta-6-desaturation of essential fatty acids in rat liver microsomes. Prostaglandins Leukot Essent Fatty Acids 58, 417–420.
92 Das, UN (2010) A defect in Δ6 and Δ5 desaturases may be a factor in the initiation and progression of insulin resistance, the metabolic syndrome and ischemic heart disease in South Asians. Lipids Health Dis 9, 130.
93 Horrobin, DF (1981) Loss of delta-6-desaturase activity as a key factor in aging. Med Hypotheses 7, 1211–1220.
94 Montuschi, P, Barnes, P & Roberts, LJ 2nd (2007) Insights into oxidative stress: the isoprostanes. Curr Med Chem 14, 703–717.
95 Oster, T & Pillot, T (2010) Docosahexaenoic acid and synaptic protection in Alzheimer's disease mice. Biochim Biophys Acta 1801, 791–798.
96 Simopoulos, AP (2008) The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med 233, 674–688.
97 Lord, RS & Bralley, JA (2008) Laboratory Evaluations for Integrative and Functional Medicine, 2nd ed. Georgia: Metametrix Institute.
98 Infante, JP & Huszagh, VA (1997) On the molecular etiology of decreased arachidonic (20:4n-6), docosapentaenoic (22:5n-6) and docosahexaenoic (22:6n-3) acids in Zellweger syndrome and other peroxisomal disorders. Mol Cell Biochem 168, 101–115.
99 Astarita, G, Jung, KM, Berchtold, NC, et al. (2010) Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. PLoS One 5, e12538.
100 Kou, J, Kovacs, GG, Hoftberger, R, et al. (2011) Peroxisomal alterations in Alzheimer's disease. Acta Neuropathol 122, 271–283.
101 Cunnane, SC (1988) Evidence that adverse effects of zinc deficiency on essential fatty acid composition in rats are independent of food intake. Br J Nutr 59, 273–278.
102 Cunnane, SC (1988) Role of zinc in lipid and fatty acid metabolism and in membranes. Prog Food Nutr Sci 12, 151–188.
103 Davidson, MH (2006) Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol 98, 27i–33i.
104 Barclay, AW, Brand-Miller, JC & Mitchell, P (2003) Glycemic index, glycemic load and diabetes in a sample of older Australians. Asia Pac J Clin Nutr Suppl. 12, S11.
105 Havel, PJ (2005) Dietary fructose: implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism. Nutr Rev 63, 133–157.
106 Basciano, H, Federico, L & Adeli, K (2005) Fructose, insulin resistance, and metabolic dyslipidemia. Nutr Metab 2, 5.
107 Kok, N, Roberfroid, M & Delzenne, N (1996) Dietary oligofructose modifies the impact of fructose on hepatic triacylglycerol metabolism. Metabolism 45, 1547–1550.
108 van der Borght, K, Kohnke, R, Goransson, N, et al. (2011) Reduced neurogenesis in the rat hippocampus following high fructose consumption. Regul Pept 167, 26–30.
109 Banks, WA (2008) The blood–brain barrier as a cause of obesity. Curr Pharm Des 14, 1606–1614.
110 Kokoeva, MV, Yin, H & Flier, JS (2005) Neurogenesis in the hypothalamus of adult mice: potential role in energy balance. Science 310, 679–683.
111 McNay, DE, Briancon, N, Kokoeva, MV, et al. (2012) Remodeling of the arcuate nucleus energy-balance circuit is inhibited in obese mice. J Clin Invest 122, 142–152.
112 Migaud, M, Batailler, M, Segura, S, et al. (2010) Emerging new sites for adult neurogenesis in the mammalian brain: a comparative study between the hypothalamus and the classical neurogenic zones. Eur J Neurosci 32, 2042–2052.
113 Pierce, AA & Xu, AW (2010) De novo neurogenesis in adult hypothalamus as a compensatory mechanism to regulate energy balance. J Neurosci 30, 723–730.
114 Funari, VA, Crandall, JE & Tolan, DR (2007) Fructose metabolism in the cerebellum. Cerebellum 6, 130–140.
115 Dauncey, MJ (2009) New insights into nutrition and cognitive neuroscience. Proc Nutr Soc 68, 408–415.
116 Kamphuis, PJ & Scheltens, P (2010) Can nutrients prevent or delay onset of Alzheimer's disease? J Alzheimers Dis 20, 765–775.
117 Liu, J & Ames, BN (2005) Reducing mitochondrial decay with mitochondrial nutrients to delay and treat cognitive dysfunction, Alzheimer's disease, and Parkinson's disease. Nutr Neurosci 8, 67–89.
118 Pieczenik, SR & Neustadt, J (2007) Mitochondrial dysfunction and molecular pathways of disease. Exp Mol Pathol 83, 84–92.
119 Conquer, JA, Tierney, MC, Zecevic, J, et al. (2000) Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. Lipids 35, 1305–1312.
120 Rinaldi, P, Polidori, MC, Metastasio, A, et al. (2003) Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol Aging 24, 915–919.
121 Quadri, P, Fragiacomo, C, Pezzati, R, et al. (2004) Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia. Am J Clin Nutr 80, 114–122.
122 Baldeiras, I, Santana, I, Proenca, MT, et al. (2008) Peripheral oxidative damage in mild cognitive impairment and mild Alzheimer's disease. J Alzheimers Dis 15, 117–128.
123 Dysken, MW, Sano, M, Asthana, S, et al. (2014) Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA 311, 33–44.
124 Littlejohns, TJ, Henley, WE, Lang, IA, et al. (2014) Vitamin D and the risk of dementia and Alzheimer disease. Neurology 83, 920–928.
125 Douaud, G, Refsum, H, de Jager, CA, et al. (2013) Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci U S A 110, 9523–9528.
126 Balk, E, Chung, M, Raman, G, et al. (2006) B vitamins and berries and age-related neurodegenerative disorders. Evid Rep Technol Assess 1–161.
127 Aisen, PS, Schneider, LS, Sano, M, et al. (2008) High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA 300, 1774–1783.
128 Morris, MC, Evans, DA, Schneider, JA, et al. (2006) Dietary folate and vitamins B-12 and B-6 not associated with incident Alzheimer's disease. J Alzheimer's Dis 9, 435–443.
129 Smith, C, Marks, AD & Lieberman, M (2005) Protein digestion and amino acid absorption. In Marks' Basic Medical Biochemistry: A Clinical Approach, p. 695 [Smith, C, Marks, AD and Lieberman, M, editors]. Philadelphia: Lippincott Williams & Wilkins.
130 Sawada, M, Hirata, Y, Arai, H, et al. (1987) Tyrosine hydroxylase, tryptophan hydroxylase, biopterin, and neopterin in the brains of normal controls and patients with senile dementia of Alzheimer type. J Neurochem 48, 760–764.
131 Vrecko, K, Birkmayer, JG & Krainz, J (1993) Stimulation of dopamine biosynthesis in cultured PC 12 phaeochromocytoma cells by the coenzyme nicotinamide adeninedinucleotide (NADH). J Neural Transm Park Dis Dement Sect 5, 147–156.
132 O'Keeffe, ST (2000) Thiamine deficiency in elderly people. Age Ageing 29, 99–101.
133 Gibson, GE & Blass, JP (2007) Thiamine-dependent processes and treatment strategies in neurodegeneration. Antioxid Redox Signal 9, 1605–1619.
134 Gibson, GE, Sheu, KF, Blass, JP, et al. (1988) Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease. Arch Neurol 45, 836–840.
135 Wyatt, DT, Nelson, D & Hillman, RE (1991) Age-dependent changes in thiamin concentrations in whole blood and cerebrospinal fluid in infants and children. Am J Clin Nutr 53, 530–536.
136 Singleton, CK & Martin, PR (2001) Molecular mechanisms of thiamine utilization. Curr Mol Med 1, 197–207.
137 Langlais, PJ & Zhang, SX (1993) Extracellular glutamate is increased in thalamus during thiamine deficiency-induced lesions and is blocked by MK-801. J Neurochem 61, 2175–2182.
138 Heroux, M, Raghavendra Rao, VL, Lavoie, J, et al. (1996) Alterations of thiamine phosphorylation and of thiamine-dependent enzymes in Alzheimer's disease. Metab Brain Dis 11, 81–88.
139 Mastrogiacoma, F, Bettendorff, L, Grisar, T, et al. (1996) Brain thiamine, its phosphate esters, and its metabolizing enzymes in Alzheimer's disease. Ann Neurol 39, 585–591.
140 Mastrogiacoma, F, Lindsay, JG, Bettendorff, L, et al. (1996) Brain protein and alpha-ketoglutarate dehydrogenase complex activity in Alzheimer's disease. Ann Neurol 39, 592–598.
141 Matsushita, S, Miyakawa, T, Maesato, H, et al. (2008) Elevated cerebrospinal fluid tau protein levels in Wernicke's encephalopathy. Alcohol Clin Exp Res 32, 1091–1095.
142 Zhang, Q, Yang, G, Li, W, et al. (2011) Thiamine deficiency increases beta-secretase activity and accumulation of beta-amyloid peptides. Neurobiol Aging 32, 42–53.
143 Karuppagounder, SS, Xu, H, Shi, Q, et al. (2009) Thiamine deficiency induces oxidative stress and exacerbates the plaque pathology in Alzheimer's mouse model. Neurobiol Aging 30, 1587–1600.
144 Markesbery, WR (1997) Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 23, 134–147.
145 Perry, G, Cash, AD & Smith, MA (2002) Alzheimer disease and oxidative stress. J Biomed Biotechnol 2, 120–123.
146 Micronutrient Information Centre, Linus Pauling Institute, Micronutrient Research For Optimum Health, Oregon State University (2014) Vitamin B12 . http://lpi.oregonstate.edu/infocenter/vitamins/vitaminB12/#alzheimer.
147 Seshadri, S, Beiser, A, Selhub, J, et al. (2002) Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346, 476–483.
148 Joseph, JA, Denisova, N, Fisher, D, et al. (1998) Membrane and receptor modifications of oxidative stress vulnerability in aging. Nutritional considerations. Ann N Y Acad Sci 854, 268–276.
149 Ames, BN, Cathcart, R, Schwiers, E, et al. (1981) Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 78, 6858–6862.
150 Hageman, GJ & Stierum, RH (2001) Niacin, poly(ADP-ribose) polymerase-1 and genomic stability. Mutat Res 475, 45–56.
151 Nakashima, Y & Suzue, R (1984) Influence of nicotinic acid on cerebroside synthesis in the brain of developing rats. J Nutr Sci Vitaminol 30, 525–534.
152 Melo, SS, Meirelles, MS, Jordao Junior, AA, et al. (2000) Lipid peroxidation in nicotinamide-deficient and nicotinamide-supplemented rats. Int J Vitam Nutr Res 70, 321–323.
153 Morris, MC, Evans, DA, Bienias, JL, et al. (2004) Dietary niacin and the risk of incident Alzheimer's disease and of cognitive decline. J Neurol Neurosurg Psychiatry 75, 1093–1099.
154 Battaglia, A, Bruni, G, Ardia, A, et al. (1989) Nicergoline in mild to moderate dementia. A multicenter, double-blind, placebo-controlled study. J Am Geriatr Soc 37, 295–302.
155 Malouf, R & Grimley Evans, J (2003) The effect of vitamin B6 on cognition. The Cochrane Database of Systematic Reviews 2003, issue 4 , CD004393.
156 Wakimoto, P & Block, G (2001) Dietary intake, dietary patterns, and changes with age: an epidemiological perspective. J Gerontol A Biol Sci Med Sci 56, 65–80.
157 Coker, M, de Klerk, JB, Poll-The, BT, et al. (1996) Plasma total odd-chain fatty acids in the monitoring of disorders of propionate, methylmalonate and biotin metabolism. J Inherit Metab Dis 19, 743–751.
158 Umhau, JC, Dauphinais, KM, Patel, SH, et al. (2006) The relationship between folate and docosahexaenoic acid in men. Eur J Clin Nutr 60, 352–357.
159 Pita, ML & Delgado, MJ (2000) Folate administration increases n-3 polyunsaturated fatty acids in rat plasma and tissue lipids. Thromb Haemost 84, 420–423.
160 Hirono, H & Wada, Y (1978) Effects of dietary folate deficiency on developmental increase of myelin lipids in rat brain. J Nutr 108, 766–772.
161 Rogaev, EI, Lukiw, WJ, Lavrushina, O, et al. (1994) The upstream promoter of the beta-amyloid precursor protein gene (APP) shows differential patterns of methylation in human brain. Genomics 22, 340–347.
162 Miller, AL (2003) The methionine–homocysteine cycle and its effects on cognitive diseases. Altern Med Rev 8, 7–19.
163 Lehmann, M, Gottfries, CG & Regland, B (1999) Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dement Geriatr Cogn Disord 10, 12–20.
164 Nilsson, K, Gustafson, L & Hultberg, B (2002) Relation between plasma homocysteine and Alzheimer's disease. Dement Geriatr Cogn Disord 14, 7–12.
165 Nilsson, K, Gustafson, L & Hultberg, B (2001) Improvement of cognitive functions after cobalamin/folate supplementation in elderly patients with dementia and elevated plasma homocysteine. Int J Geriatr Psychiatry 16, 609–614.
166 Snowdon, DA, Tully, CL, Smith, CD, et al. (2000) Serum folate and the severity of atrophy of the neocortex in Alzheimer disease: findings from the Nun study. Am J Clin Nutr 71, 993–998.
167 Kwok, T, Tang, C, Woo, J, et al. (1998) Randomized trial of the effect of supplementation on the cognitive function of older people with subnormal cobalamin levels. Int J Geriatr Psychiatry 13, 611–616.
168 Evers, S, Koch, HG, Grotemeyer, KH, et al. (1997) Features, symptoms, and neurophysiological findings in stroke associated with hyperhomocysteinemia. Arch Neurol 54, 1276–1282.
169 Chambers, JC, Ueland, PM, Obeid, OA, et al. (2000) Improved vascular endothelial function after oral B vitamins: an effect mediated through reduced concentrations of free plasma homocysteine. Circulation 102, 2479–2483.
170 Christen, Y (2000) Oxidative stress and Alzheimer disease. Am J Clin Nutr 71, 621S–629S.
171 Ho, PI, Ortiz, D, Rogers, E, et al. (2002) Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res 70, 694–702.
172 White, AR, Huang, X, Jobling, MF, et al. (2001) Homocysteine potentiates copper- and amyloid beta peptide-mediated toxicity in primary neuronal cultures: possible risk factors in the Alzheimer's-type neurodegenerative pathways. J Neurochem 76, 1509–1520.
173 Ho, PI, Collins, SC, Dhitavat, S, et al. (2001) Homocysteine potentiates beta-amyloid neurotoxicity: role of oxidative stress. J Neurochem 78, 249–253.
174 Kruman, II, Culmsee, C, Chan, SL, et al. (2000) Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 20, 6920–6926.
175 Olney, JW, Price, MT, Salles, KS, et al. (1987) l-Homocysteic acid: an endogenous excitotoxic ligand of the NMDA receptor. Brain Res Bull 19, 597–602.
176 James, SJ, Melnyk, S, Pogribna, M, et al. (2002) Elevation in S-adenosylhomocysteine and DNA hypomethylation: potential epigenetic mechanism for homocysteine-related pathology. J Nutr 132, Suppl. 8, 2361S–2366S.
177 West, RL, Lee, JM & Maroun, LE (1995) Hypomethylation of the amyloid precursor protein gene in the brain of an Alzheimer's disease patient. J Mol Neurosci 6, 141–146.
178 Selley, ML (2007) A metabolic link between S-adenosylhomocysteine and polyunsaturated fatty acid metabolism in Alzheimer's disease. Neurobiol Aging 28, 1834–1839.
179 Werstuck, GH, Lentz, SR, Dayal, S, et al. (2001) Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest 107, 1263–1273.
180 Walker, AK, Jacobs, RL, Watts, JL, et al. (2011) A conserved SREBP-1/phosphatidylcholine feedback circuit regulates lipogenesis in metazoans. Cell 147, 840–852.
181 Vance, DE, Walkey, CJ & Cui, Z (1997) Phosphatidylethanolamine N-methyltransferase from liver. Biochim Biophys Acta 1348, 142–150.
182 Resseguie, M, Song, J, Niculescu, MD, et al. (2007) Phosphatidylethanolamine N-methyltransferase (PEMT) gene expression is induced by estrogen in human and mouse primary hepatocytes. FASEB J 21, 2622–2632.
183 Michel, V, Yuan, Z, Ramsubir, S, et al. (2006) Choline transport for phospholipid synthesis. Exp Biol Med 231, 490–504.
184 Wecker, L (1990) Dietary choline: a limiting factor for the synthesis of acetylcholine by the brain. Adv Neurol 51, 139–145.
185 Slotkin, TA, Nemeroff, CB, Bissette, G, et al. (1994) Overexpression of the high affinity choline transporter in cortical regions affected by Alzheimer's disease. Evidence from rapid autopsy studies. J Clin Invest 94, 696–702.
186 Miller, BL, Jenden, DJ, Cummings, JL, et al. (1986) Abnormal erythrocyte choline and influx in Alzheimer's disease. Life Sci 38, 485–490.
187 Balmer, JE & Blomhoff, R (2002) Gene expression regulation by retinoic acid. J Lipid Res 43, 1773–1808.
188 Khanna, A & Reddy, TS (1983) Effect of undernutrition and vitamin A deficiency on the phospholipid composition of rat tissues at 21 days of age. I. Liver, spleen and kidney. Int J Vitam Nutr Res 53, 3–8.
189 Oliveros, LB, Domeniconi, MA, Vega, VA, et al. (2007) Vitamin A deficiency modifies lipid metabolism in rat liver. Br J Nutr 97, 263–272.
190 Koryakina, A, Aeberhard, J, Kiefer, S, et al. (2009) Regulation of secretases by all-trans-retinoic acid. FEBS J 276, 2645–2655.
191 Goodman, AB & Pardee, AB (2003) Evidence for defective retinoid transport and function in late onset Alzheimer's disease. Proc Natl Acad Sci U S A 100, 2901–2905.
192 Shudo, K, Fukasawa, H, Nakagomi, M, et al. (2009) Towards retinoid therapy for Alzheimer's disease. Curr Alzheimer Res 6, 302–311.
193 Tippmann, F, Hundt, J, Schneider, A, et al. (2009) Up-regulation of the alpha-secretase ADAM10 by retinoic acid receptors and acitretin. FASEB J 23, 1643–1654.
194 Corcoran, JP, So, PL & Maden, M (2004) Disruption of the retinoid signalling pathway causes a deposition of amyloid beta in the adult rat brain. Eur J Neurosci 20, 896–902.
195 Husson, M, Enderlin, V, Delacourte, A, et al. (2006) Retinoic acid normalizes nuclear receptor mediated hypo-expression of proteins involved in beta-amyloid deposits in the cerebral cortex of vitamin A deprived rats. Neurobiol Dis 23, 1–10.
196 Acin-Perez, R, Hoyos, B, Zhao, F, et al. (2010) Control of oxidative phosphorylation by vitamin A illuminates a fundamental role in mitochondrial energy homoeostasis. FASEB J 24, 627–636.
197 Leung, WC, Hessel, S, Meplan, C, et al. (2009) Two common single nucleotide polymorphisms in the gene encoding beta-carotene 15,15′-monoxygenase alter beta-carotene metabolism in female volunteers. FASEB J 23, 1041–1053.
198 Buell, JS & Dawson-Hughes, B (2008) Vitamin D and neurocognitive dysfunction: preventing “D”ecline? Mol Aspects Med 29, 415–422.
199 Sato, Y, Asoh, T & Oizumi, K (1998) High prevalence of vitamin D deficiency and reduced bone mass in elderly women with Alzheimer's disease. Bone 23, 555–557.
200 Scott, TM, Peter, I, Tucker, KL, et al. (2006) The Nutrition, Aging, and Memory in Elders (NAME) study: design and methods for a study of micronutrients and cognitive function in a homebound elderly population. Int J Geriatr Psychiatry 21, 519–528.
201 Ogihara, T, Miya, K & Morimoto, S (1990) Possible participation of calcium-regulating factors in senile dementia in elderly female subjects. Gerontology 36, Suppl. 1, 25–30.
202 Luckhaus, C, Mahabadi, B, Grass-Kapanke, B, et al. (2009) Blood biomarkers of osteoporosis in mild cognitive impairment and Alzheimer's disease. J Neural Transm 116, 905–911.
203 Tysiewicz-Dudek, M, Pietraszkiewicz, F & Drozdzowska, B (2008) Alzheimer's disease and osteoporosis: common risk factors or one condition predisposing to the other? Ortop Traumatol Rehabil 10, 315–323.
204 Sutherland, MK, Somerville, MJ, Yoong, LK, et al. (1992) Reduction of vitamin D hormone receptor mRNA levels in Alzheimer as compared to Huntington hippocampus: correlation with calbindin-28k mRNA levels. Brain Res Mol Brain Res 13, 239–250.
205 Gezen-Ak, D, Dursun, E, Ertan, T, et al. (2007) Association between vitamin D receptor gene polymorphism and Alzheimer's disease. Tohoku J Exp Med 212, 275–282.
206 Baas, D, Prufer, K, Ittel, ME, et al. (2000) Rat oligodendrocytes express the vitamin D(3) receptor and respond to 1,25-dihydroxyvitamin D(3). Glia 31, 59–68.
207 Alvarez, JA & Ashraf, A (2010) Role of vitamin D in insulin secretion and insulin sensitivity for glucose homeostasis. Int J Endocrinol 2010, 351–385.
208 Wehr, E, Pilz, S, Boehm, BO, et al. (2010) Association of vitamin D status with serum androgen levels in men. Clin Endocrinol (Oxf) 73, 243–248.
209 Chu, LW, Tam, S, Lee, PW, et al. (2008) Bioavailable testosterone is associated with a reduced risk of amnestic mild cognitive impairment in older men. Clin Endocrinol (Oxf) 68, 589–598.
210 Hogervorst, E, Bandelow, S, Combrinck, M, et al. (2004) Low free testosterone is an independent risk factor for Alzheimer's disease. Exp Gerontol 39, 1633–1639.
211 Kinuta, K, Tanaka, H, Moriwake, T, et al. (2000) Vitamin D is an important factor in estrogen biosynthesis of both female and male gonads. Endocrinology 141, 1317–1324.
212 Jimenez-Jimenez, FJ, de Bustos, F, Molina, JA, et al. (1997) Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Alzheimer's disease. J Neural Transm 104, 703–710.
213 Perkins, AJ, Hendrie, HC, Callahan, CM, et al. (1999) Association of antioxidants with memory in a multiethnic elderly sample using the Third National Health and Nutrition Examination Survey. Am J Epidemiol 150, 37–44.
214 Vuletic, S, Peskind, ER, Marcovina, SM, et al. (2005) Reduced CSF PLTP activity in Alzheimer's disease and other neurologic diseases; PLTP induces ApoE secretion in primary human astrocytes in vitro . J Neurosci Res 80, 406–413.
215 Desrumaux, C, Risold, PY, Schroeder, H, et al. (2005) Phospholipid transfer protein (PLTP) deficiency reduces brain vitamin E content and increases anxiety in mice. FASEB J 19, 296–297.
216 Yatin, SM, Varadarajan, S & Butterfield, DA (2000) Vitamin E prevents Alzheimer's amyloid beta-peptide (1–42)-induced neuronal protein oxidation and reactive oxygen species production. J Alzheimers Dis 2, 123–131.
217 Butterfield, DA, Koppal, T, Subramaniam, R, et al. (1999) Vitamin E as an antioxidant/free radical scavenger against amyloid beta-peptide-induced oxidative stress in neocortical synaptosomal membranes and hippocampal neurons in culture: insights into Alzheimer's disease. Rev Neurosci 10, 141–149.
218 Rota, C, Rimbach, G, Minihane, AM, et al. (2005) Dietary vitamin E modulates differential gene expression in the rat hippocampus: potential implications for its neuroprotective properties. Nutr Neurosci 8, 21–29.
219 Cutler, RG, Kelly, J, Storie, K, et al. (2004) Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci U S A 101, 2070–2075.
220 Briefel, RR, Bialostosky, K, Kennedy-Stephenson, J, et al. (2000) Zinc intake of the U.S. population: findings from the third National Health and Nutrition Examination Survey, 1988–1994. J Nutr 130, Suppl. 5S, 1367S–1373S.
221 Tully, CL, Snowdon, DA & Markesbery, WR (1995) Serum zinc, senile plaques, and neurofibrillary tangles: findings from the Nun Study. Neuroreport 6, 2105–2108.
222 Cuajungco, MP & Faget, KY (2003) Zinc takes the center stage: its paradoxical role in Alzheimer's disease. Brain Res Brain Res Rev 41, 44–56.
223 Loef, M, von Stillfried, N & Walach, H (2012) Zinc diet and Alzheimer's disease: a systematic review. Nutr Neurosci 15, 2–12.
224 Stoltenberg, M, Bush, AI, Bach, G, et al. (2007) Amyloid plaques arise from zinc-enriched cortical layers in APP/PS1 transgenic mice and are paradoxically enlarged with dietary zinc deficiency. Neuroscience 150, 357–369.
225 Black, MM (2003) Micronutrient deficiencies and cognitive functioning. J Nutr 133, Suppl. 2, 3927S–3931S.
226 Bhatnagar, S & Taneja, S (2001) Zinc and cognitive development. Br J Nutr 85, Suppl. 2, S139–S145.
227 Huang, X, Atwood, CS, Hartshorn, MA, et al. (1999) The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38, 7609–7616.
228 Huang, X, Cuajungco, MP, Atwood, CS, et al. (2000) Alzheimer's disease, beta-amyloid protein and zinc. J Nutr 130, Suppl. 5S, 1488S–1492S.
229 Atamna, H (2006) Heme binding to amyloid-beta peptide: mechanistic role in Alzheimer's disease. J Alzheimers Dis 10, 255–266.
230 Atamna, H & Boyle, K (2006) Amyloid-beta peptide binds with heme to form a peroxidase: relationship to the cytopathologies of Alzheimer's disease. Proc Natl Acad Sci U S A 103, 3381–3386.
231 Sensi, SL & Jeng, JM (2004) Rethinking the excitotoxic ionic milieu: the emerging role of Zn(2+) in ischemic neuronal injury. Curr Mol Med 4, 87–111.
232 Furuta, A, Price, DL, Pardo, CA, et al. (1995) Localization of superoxide dismutases in Alzheimer's disease and Down's syndrome neocortex and hippocampus. Am J Pathol 146, 357–367.
233 Leissring, MA, Farris, W, Wu, X, et al. (2004) Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria. Biochem J 383, 439–446.
234 Jayasooriya, AP, Ackland, ML, Mathai, ML, et al. (2005) Perinatal omega-3 polyunsaturated fatty acid supply modifies brain zinc homeostasis during adulthood. Proc Natl Acad Sci U S A 102, 7133–7138.
235 Suphioglu, C, De Mel, D, Kumar, L, et al. (2010) The omega-3 fatty acid, DHA, decreases neuronal cell death in association with altered zinc transport. FEBS Lett 584, 612–618.
236 Potocnik, FC, van Rensburg, SJ, Hon, D, et al. (2006) Oral zinc augmentation with vitamins A and D increases plasma zinc concentration: implications for burden of disease. Metab Brain Dis 21, 139–147.
237 Wang, J, Fivecoat, H, Ho, L, et al. (2010) The role of Sirt1: at the crossroad between promotion of longevity and protection against Alzheimer's disease neuropathology. Biochim Biophys Acta 1804, 1690–1694.
238 Donmez, G, Wang, D, Cohen, DE, et al. (2010) SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10 . Cell 142, 320–332.
239 Costa, RM, Drew, C & Silva, AJ (2005) Notch to remember. Trends Neurosci 28, 429–435.
240 Bonda, DJ, Lee, HG, Camins, A, et al. (2011) The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations. Lancet Neurol 10, 275–279.
241 Civitarese, AE, Carling, S, Heilbronn, LK, et al. (2007) Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. PLoS Med 4, e76.
242 Xue, B, Yang, Z, Wang, X, et al. (2012) Omega-3 polyunsaturated fatty acids antagonize macrophage inflammation via activation of AMPK/SIRT1 pathway. PLOS ONE 7, e45990.
243 Wu, A, Ying, Z & Gomez-Pinilla, F (2007) Omega-3 fatty acids supplementation restores mechanisms that maintain brain homeostasis in traumatic brain injury. J Neurotrauma 24, 1587–1595.
244 Hong, YT, Veenith, T, Dewar, D, et al. (2014) Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury. JAMA Neurol 71, 23–31.
245 Lye, TC & Shores, EA (2000) Traumatic brain injury as a risk factor for Alzheimer's disease: a review. Neuropsychol Rev 10, 115–129.
246 Nemetz, PN, Leibson, C, Naessens, JM, et al. (1999) Traumatic brain injury and time to onset of Alzheimer's disease: a population-based study. Am J Epidemiol 149, 32–40.
247 Borra, MT, Smith, BC & Denu, JM (2005) Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 280, 17187–17195.
248 Allard, JS, Perez, E, Zou, S, et al. (2009) Dietary activators of Sirt1. Mol Cell Endocrinol 299, 58–63.
249 Maher, P, Akaishi, T & Abe, K (2006) Flavonoid fisetin promotes ERK-dependent long-term potentiation and enhances memory. Proc Natl Acad Sci U S A 103, 16568–16573.
250 Ansari, MA, Abdul, HM, Joshi, G, et al. (2009) Protective effect of quercetin in primary neurons against Abeta(1–42): relevance to Alzheimer's disease. J Nutr Biochem 20, 269–275.
251 Craft, NE, Haitema, TB, Garnett, KM, et al. (2004) Carotenoid, tocopherol, and retinol concentrations in elderly human brain. J Nutr Health Aging 8, 156–162.
252 Johnson, EJ (2012) A possible role for lutein and zeaxanthin in cognitive function in the elderly. Am J Clin Nutr 96, 1161S–1165S.
253 GM, Cole, Lim, GP, Yang, F, et al. (2005) Prevention of Alzheimer's disease: omega-3 fatty acid and phenolic anti-oxidant interventions. Neurobiol Aging 26, Suppl. 1, 133–136.
254 Venkatesan, P & Rao, MN (2000) Structure–activity relationships for the inhibition of lipid peroxidation and the scavenging of free radicals by synthetic symmetrical curcumin analogues. J Pharm Pharmacol 52, 1123–1128.
255 Aggarwal, BB, Kumar, A & Bharti, AC (2003) Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 23, 363–398.
256 Lim, GP, Chu, T, Yang, F, et al. (2001) The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 21, 8370–8377.
257 Baum, L, Lam, CW, Cheung, SK, et al. (2008) Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 28, 110–113.
258 Ringman, JM, Frautschy, SA, Teng, E, et al. (2012) Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res Ther 4, 43.
259 Hyung, SJ, DeToma, AS, Brender, JR, et al. (2013) Insights into antiamyloidogenic properties of the green tea extract ( − )-epigallocatechin-3-gallate toward metal-associated amyloid-beta species. Proc Natl Acad Sci U S A 110, 3743–3748.
260 Lee, MJ, Maliakal, P, Chen, L, et al. (2002) Pharmacokinetics of tea catechins after ingestion of green tea and ( − )-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol Biomarkers Prev 11, 1025–1032.
261 Vepsalainen, S, Koivisto, H, Pekkarinen, E, et al. (2013) Anthocyanin-enriched bilberry and blackcurrant extracts modulate amyloid precursor protein processing and alleviate behavioral abnormalities in the APP/PS1 mouse model of Alzheimer's disease. J Nutr Biochem 24, 360–370.
262 Hartman, RE, Shah, A, Fagan, AM, et al. (2006) Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer's disease. Neurobiol Dis 24, 506–515.
263 Ye, J, Meng, X, Yan, C, et al. (2010) Effect of purple sweet potato anthocyanins on beta-amyloid-mediated PC-12 cells death by inhibition of oxidative stress. Neurochem Res 35, 357–365.
264 Gutierres, JM, Carvalho, FB & Schetinger, MR (2014) Anthocyanins restore behavioral and biochemical changes caused by streptozotocin-induced sporadic dementia of Alzheimer's type. Life Sci 96, 7–17.
265 Zeisel, SH & Blusztajn, JK (1994) Choline and human nutrition. Ann Rev Nutr 14, 269–296.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

British Journal of Nutrition
  • ISSN: 0007-1145
  • EISSN: 1475-2662
  • URL: /core/journals/british-journal-of-nutrition
Please enter your name
Please enter a valid email address
Who would you like to send this to? *

CAPTCHA *

Skip to the audio challenge
×

Keywords

Metrics

Altmetric attention score

Cancel
Confirm
×